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There are several reviews on NO and hydrogen sulﬁde (H2S) and their role in vascular diseases in the current relevant literature.
The aim of this review is to discuss, within the limits of present knowledge, the interconnection between these two
gasotransmitters in vascular function. In particular, the review focuses on the role played by the balance between the NO and H2S
pathways in either physiological or pathological conditions. The distinction between physiology and pathology has been made in
order to dissect the molecular basis of this crosstalk, highlighting how and if this balance varies, depending upon the vascular
status. Perspectives and possible novel therapeutic approaches are also discussed.
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Introduction
In 1980s the revolutionary concept that a gas, that is, NO,
produced in our body could act as a mediator surprised the
scientiﬁc community. It was even more surprising when it
was discovered that in the vasculature, NO, a gas, could
selectively activate a key enzyme such as the soluble
guanylate cyclase (sGC) leading to an increase of (cGMP)
biosynthesis. The ﬁrst hints of this mechanism were given in
1978 by Murad who demonstrated that nitroglycerin, by
activating sGC, increased cGMP levels (Mittal et al., 1978).
Then, in 1980, Furchgott hypothesized the existence of
an endothelial derived relaxing factor (EDRF) as a mediator
of acetylcholine-induced vasorelaxation (Furchgott and
Zawadzki, 1980). Finally, Ignarro identiﬁed NO as EDRF
(Ignarro et al., 1988). All three scientists shared the Nobel
Prize in Medicine in 1998.
Nowadays, NO, together with carbonmonoxide (CO) and
hydrogen sulfide (H2S), constitute a family of endogenous
mediators that share the characteristic to be a gas. Among
them, H2S was the last to be identiﬁed and it is the only one
that has a chemical structure in thre dimesninos, as distict
from the planar structure of NO and CO. This discovery of
the third gaseous endogenous molecule allowed the scientiﬁc
community to coin the term ‘gasotransmitters’ to refer to this
growing class of mediators and introducing a novel class of
endogenous mediators (Wang, 2002; Szabo, 2007). The
gasotransmitter is a small, labile molecule biosynthesized in
the body by enzymic reactions with a very short half-life,
ranging from seconds tominutes. Being a gas, this transmitter
molecule freely permeates the cell membranes without
speciﬁc transporters, reaching molecular targets relatively far
from the site of its biosynthesis. This characteristic unveils a
new concept:The biological effect triggered by the gasotransmitter
is not necessarily due to the interaction with a single specific target.
This concept, apparently obvious, has changed radically the
classical idea of ligand–receptor interaction in pharmacology.
The gasotransmitter, due to its unique chemical nature, once
produced, freely travels through the cells, interacting with
many different molecular structures.
The gas connection: NO and H2S in
physiology
NO
In the vasculature, NO is generatedwithin the endotheliumas
a product of the enzymic reaction of endothelial NOS
(eNOS) with its substrate L-arginine together with molecular
oxygen and reduced NADPH as co-substrates. The NO
biosynthesis requires the dimerization of two molecules of
eNOS and the presence of several co-factors such as ﬂavin
adenine dinucleotide (FAD), ﬂavin mononucleotide (FMN),
(6R-)5,6,7,8-tetrahydro-L-biopterin (BH4), calmodulin and
iron protoporphyrin IX (haem) (see Forstermann and Sessa,
2012; Zhao et al., 2015). Once NO has been generated within
the endothelial cells, it diffuses to the vascular smoothmuscle
cells and binds the haem group of sGC, leading to the
conversion of GTP to cGMP. This second messenger, through
a PKG dependent mechanism, activates a downstream
signalling that induces a decrease of the intracellular Ca2+
concentration. This decrease prevents myosin phosp-
horylation by myosin light chain kinase, with consequent
vasorelaxation (Word et al., 1994; Mizuno et al., 2008). This
pathway is turned off by the catabolic action ofPDE, enzymes
that degrade cGMP to its inactive metabolite, 50-GMP (Conti
and Beavo, 2007).
During its travel through the cells, NO exerts another
essential role in modulating cellular signalling, but in a
cGMP-independent manner. This alternative signalling role
entails the redox reaction between NO and the thiol group
of L-cysteine, generating a covalent modiﬁcation of protein
cysteine thiols with a formation of a new chemical entity,
called S-nitrosothiols (SNO). However, it has been recently
shown that the addition of the NO moiety can be catalysed
by a class of enzymes called nitrosylases (Foster et al., 2003;
Stamler and Hess, 2010). This reversible, rapid reaction is
called S-nitrosylation. The importance of S-nitrosylation is
well recognized, and it is now considered as an essential
molecular mechanism for modulating cellular function and
redox signalling (i.e. enzymic activity, subcellular
localization, protein–protein interaction and protein
stability). Considering the chemical nature of the
S-nitrosylation, it is intuitive that a large number of proteins
(many hundreds) may undergo this post-translational
modiﬁcation and this could explain the multiplicity of
actions of NO. As with any other mechanism of transduction,
S-nitrosylation is a transient phenomenon as other enzymic
reactions readily remove the NO group from proteins
(denitrosylation), modulating signal transduction (Beigi
et al., 2012). So far, two enzymic denitrosylation systems have
been identiﬁed- the thioredoxin (TRX)/TR system and the
GSH/GSNO system. For both of them, an important
regulatory function has been demonstrated, under
physiological conditions (Benhar et al., 2009; Forrester et al.,
2009; Anand and Stamler, 2012). In the blood vessel wall,
S-nitrosylation/denitrosylation of connexin plays a primary
role in heterocellular communication, regulating the
functions of the gap junction between endothelium and
smooth muscle cells (Straub et al., 2011). Dysregulation of
this system is involved in several diseases such as heart
failure, stroke, preeclampsia and pulmonary hypertension
(Moya et al., 2002; Bryan et al., 2008; Kunieda et al., 2008;
Foster et al., 2009; Gonzalez et al., 2009; Que et al., 2009).
These two different signal transduction pathways only
appear to be separate. The NO/sGC/cGMP pathway
selectively activates PKG and its speciﬁc downstream
effectors that amplify the signal leading to vasorelaxation.
On the contrary, S-nitrosylation generates a wide pattern of
nitrosylated proteins, responsible for different actions of
NO in vascular tissues. However, an interaction between
these two different signalling pathways has been suggested.
For instance, the S-nitrosylation/denitrosylation system can
act on the NO/sGC/PDE pathway, as the S-nitrosylation of
PDE inhibits the catabolic activity of this enzyme (Murray
et al., 2008; Lima et al., 2010) leading to an increased level
of cGMP.
Hydrogen sulfide
Similar to NO, H2S is a vasodilating mediator. The ﬁrst study
that showed the vasodilatory properties of H2S was published
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by Hosoki et al., (1997). In this pioneering paper, the authors
demonstrated that H2S donors induce vasorelaxation by
themselves and potentiate NO-donor induced vasorelaxation
in rat thoracic aorta, giving the ﬁrst hints of a possible
interaction between NO and H2S (Hosoki et al., 1997).
In mammalian tissues, H2S can be produced via both
enzymic and non-enzymic pathways, although the enzymic
path (trans-sulfuration pathway) generates the majority of
H2S in the body. Within the vessels, the production of H2S
is provided by different enzymes expressed in both
endothelium and smooth muscle cells. These two locations
represents the main difference from the biosynthesis of
NO which is, instead, generated only within endothelium
by eNOS. Cystathionine β synthase (CBS) is the best
characterized H2S generating enzyme and this protein is
considered to be the main source of H2S in the CNS (Abe
and Kimura, 1996; Eto and Kimura, 2002; Miles and Kraus,
2004). However, it is also highly expressed in peripheral
tissues, including the vasculature (Hosoki et al., 1997;
Fiorucci et al., 2006; Zhang et al., 2013; Vellecco et al.,
2016b; Szabo et al., 2013; Bucci et al., 2014). Another
enzyme, cystathionine γ lyase (CSE or CGL or CTH), is the
main H2S generating enzyme in the vascular system and is
found in both endothelium and smooth muscle cells.
However, CSE expression has been detected also in
non-vascular smooth muscle and skeletal muscle (Fiorucci
et al., 2006; Vellecco et al., 2016a; Bucci et al., 2012; Zhao
et al., 2001). Two other H2S-producing enzymes,
3-mercaptopyruvate sulfur transferase (3-MST) and cysteine
aminotrasferase (CAT) are both expressed in endothelium.
However, 3-MST is also found in smooth muscle and other
non-vascular tissues, (Nagahara et al., 1998; Shibuya et al.,
2009; Módis et al., 2013; Vellecco et al., 2016a). CBS, CSE and
CAT all require the aminoacid L-cysteine as substrate and
pyridoxal 50phosphate (PLP) as cofactor. The substrate for
3MST is 3-mercaptopyruvate and this enzyme is not
independent on PLP. The substrate L-cysteine can be derived
from the diet or can be liberated from endogenous proteins.
It can also be synthesized endogenously starting from
L-methionine through the trans-sulphuration pathway. In
contrast to NO, H2S is relatively stable in body ﬂuids, but in
common with NO, it can be scavenged by haemoglobin. H2S
can be also methylated or oxidised. H2S is excreted in urine
andﬂatus as free sulfate, thiosulfate or free sulﬁde, and it is also
exhaled in breath (see Wallace and Wang, 2015). This last
property means that it is possible to detect exhaled H2S
following intravenous administration of sodium sulﬁde in
healthy human volunteers (Toombs et al., 2010) and in rats
(Insko et al., 2009), thereby conﬁrming exhaled H2S as a way
of excretion of H2S.
The ﬁrst molecular target identiﬁed for vasodilatory
activity of H2S was the KATP (Kir6.x) channel (Zhao et al.,
2001). In this study, the H2S-induced vasodilatation was
speciﬁcally inhibited by glibenclamide, a selective
inhibitor of the KATP channels. In vascular smooth muscle
cells, a direct action of H2S on KATP channel currents and
membrane potential has been demonstrated (Zhao et al.,
2001). Because, at that time, CSE expression had been
detected only in smoothmuscle cells and not in endothelium
(Zhao et al., 2001), the authors suggested a selective role of
H2S in smooth muscle cells.
In the early years, the scientiﬁc results present in the
literature did not support the original hypothesis of an
interplay between NO and H2S signalling, as suggested by
Hosoki and co-authors, but rather provided an hypothesis
of an additive or alternative vasodilating effect. In other
words, both gasotransmitters contributed to the vaso-
dilatory process, in which the endothelium-derived NO
and the smooth muscle cell-derived H2S worked in synergy.
However, the generation of eNOS/ mice in the 1990s
deﬁnitively established the primary role of NO as an
endogenous mediator in the control of blood pressure
(Stauss et al., 1999).
H2S/NO interplay in health
As for NO, a role for H2S as an endogenous mediator was
deﬁned by the generation of CSE/ mice (Yang et al.,
2008). In this study, the CSE/ mice exhibited a
hypertensive phenotype and in isolated vessels harvested
from CSE/ mice, methacholine-induced vasodilatation
was signiﬁcantly impaired. More importantly, CSE was
located also in the endothelium and its activation shown to
be Ca2+-calmodulin dependent. This paper was instrumental
in emphasizing the similarity between the NO and H2S
pathways. Indeed, both enzymes, eNOS andCSE, are expressed
in endothelium and both require Ca2+-calmodulin binding to
be activated (Yang et al., 2008). The second group of H2S
molecular targets to be identiﬁed as responsible for H2S-
induced vasorelaxation were the PDEs (Bucci et al., 2010). The
PDEs constitute a class of enzymes that hydrolyze cyclic
nucleotides cGMP and cAMP to their respective inactive
metabolites. In both rat aorta and aortic smooth muscle cells,
H2S donors increase cGMP levels in a concentration-
dependent manner. When cells are engineered to over-express
CSE, there is an elevation of intracellular cGMP production
that is prevented by treatment with propargylglycine
(PAG), a CSE inhibitor. Conﬁrmation has been obtained by
silencing CSE which causes a marked reduction of cGMP
content. Finally, in a cell-free PDE assay, nanomolar concentr-
ations of NaHS signiﬁcantly inhibited PDE activity, reducing
the catabolism of both cGMP and cAMP (Bucci et al., 2010).
Thus, NO and H2S synergistically induce cGMP increase by
acting on the same signal transduction pathway but on
different enzymes.
As observed for NO, also H2S exerts post-translational
modiﬁcations of protein, deﬁned as S-sulfhydration (Mustafa
et al., 2009; Lu et al., 2013). Indeed, endogenous H2S (and in
particular CSE-derived H2S) physiologically S-sulfydrates
proteins on the thiol group of L-cysteine residues, in
particular of GSH, leading to the formation of the –SSH
moiety. Similarly to S-nitrosylation, S-sulfydration is a
transient phenomenon as enzymic S-desulfydration of GSSH
takes place through a mitochondrial persulﬁde dioxygenase
enzyme (ETHE1) activity, that modulates the GSH status
and indirectly the -SSH proteins level (Lu et al., 2013). Much
less is known about this S-sulfydration/de-S-sulfydration
system compared to our knowledge of the corresponding
S-nitrosylation/de-S-nitrosylation system. Also, S-sulfydra-
tion involves a large number of proteins (Mustafa et al.,
2009), leading to a hypothesis that there could be
competition between nitrosylation and S-sulfhydration for
the same cysteine residues in a protein, thus allowing the
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two gasotransmitters to regulate each other (Hara et al.,
2005).
Thus, the gas paradigm in the vasculature starts to take
shape. Increased intracellular Ca2+ leads to formation of the
Ca2+-calmodulin complex that in turn activates both CSE
and eNOS, expressed in endothelium, with consequent
production of H2S and NO respectively. Both mediators are
gases and diffuse into smooth muscle cells, reaching their
own targets: sGC for NO and PDE and KATP channels for
H2S. Both gases increase cGMP levels but through two
complementary, not overlapping, mechanisms: NO activates
sGC leading to increased synthesis of cGMP while H2S
inhibits PDE decreasing the degradation of cGMP. Therefore
in the normal, healthy vasculature, the two pathways
converge on cGMP which represents the link between NO
and H2S, providing an apparently redundant system. In
addition, H2S opens the KATP channels expressed in smooth
muscle cells, allowing the efﬂux of K+ ions from the cells. This
efﬂux limits calcium inﬂux into the cells, thereby relaxing
vascular smoth muscle (see Wang, 2012). At the same time,
S-nitrosylation/de-S-nitrosylation and S-sulfydration/de-S-
sulfydration systems continuously regulate a wide range of
proteins, modulating the biochemistry of the cell in a
dynamic andmost likely controlled and coordinatedmanner.
Another possible molecular event, which has been
discussed in several excellent reviews (Fukuto et al., 2012;
Olson, 2012; Nagpure and Bian, 2016), is the possible
chemical interaction between H2S and NO. Indeed, the
reaction between NO and H2S may generate nitroxyl,
thionitrous acid and other possible compounds which could
play roles within the cardiovascular system.
NO and H2S in inflammatory-based vascular
disease
Is the relationship between the NO and H2S pathways modified in
vascular diseases? Vascular diseases represent a heterogeneous
group of disorders of the heart and the vascular network, in
which many factors differently contribute to the onset,
development and severity of the disease. It is now
well-established that the combination of genetic predis-
position and an unhealthy environment and lifestyle can
favour the appearance of vascular diseases. Hyperlipidaemia,
hyperglycaemia, cigarette smoking, obesity and hyper-
homocysteinemia are among the many risk factors for the
development of vascular diseases. All of them could be a cause
of vascular diseases, alone or in combination, giving a wide
range of these diseases in terms of the symptoms of initiation,
the sites affected (heart, kidney, coronary arteries, etc), the
severity and the disease progression. All the pathologies
included in the vascular diseases, that is, atherosclerosis, heart
failure, diabetes and hypertension, are characterized by
oxidative stress and inﬂammatory processes (Ellulu et al.,
2016) thereby sustaining the concept of inﬂammation-based
vascular diseases (IBVD). Another group of key players in the
IBVD are the ROS. Physiologically, ROS such as peroxynitrite
(ONOO), superoxide (O2
- ), hydroxyl (HO-), hydrogen
peroxide (H2O2) and hypochlorous acid (HOCl), are signal
molecules that are involved in vascular homeostasis. They
regulate oxygen sensing, apoptosis, cell proliferation,
defence from microbial injury and inﬂammatory reactions
(Zhang et al., 2007; Santilli et al., 2015). These molecules
are produced within the vessels by endothelium, smooth
muscle cells and also in adventitia (Lakshmi et al., 2009)
by several enzymic systems including mitochondrial
enzymes, xanthine oxidase, lipoxygenase and NADPH
oxidase. The vascular tissues have antioxidant systems that
continuously operate to counterbalance the ROS generated.
These include superoxide dismutase, catalase, TRX
peroxidase, GSH peroxidase and , haem oxygenase (Zhang
et al., 2007; Santilli et al., 2015). When the ROS production
overwhelms the endogenous antioxidant systems, the body
undergoes what is called oxidative stress. All the IBVD have
in common, this condition of oxidative stress and its ﬁrst
target is the endothelium. The impaired biosynthesis of
NO by eNOS is the main consequence of oxidative stress
in the endothelium, probably because, in presence of high
levels of ROS, the eNOS co-factor BH4 is readily oxidised
(Antoniades et al., 2007). This induces the uncoupling of
eNOS, with consequent generation of O2
 instead of NO
(Antoniades et al., 2007; Dikalova et al., 2016). This process
has been conﬁrmed in patients with heart failure with
preserved ejection fraction, where the oxidation of BH4 to
BH2 is associated with eNOS uncoupling (Yamamoto
et al., 2015). The impairment of NO biosynthesis has a wide
ranging effect on many aspects of vascular function. In
healthy tissues, beyond its capacity to dilate vessels, NO
reduces oxidation of LDL, reduces platelet reactivity and
decreases leukocyte stickiness, all changes that protect the
vasculature. Therefore, the impairment of NO release due
to endothelial dysfunction induces vasoconstriction,
procoagulability and arterial stiffness that maintain a
vicious cycle in IBVD. Another element that contributes to
the impairment of NO biosynthesis associated with IBVD
is the protein caveolin-1 (CAV-1). In normal, resting
conditions, eNOS is bound to CAV-1, a resident protein of
caveolae that keeps eNOS in a less active state. When
intracellular Ca2+ rises, the Ca2+-calmodulin complex binds
eNOS and, together with HSP90, displaces eNOS from the
negative control of CAV-1, leading to activation of the
enzyme (Bucci et al., 2000; Gratton et al., 2000). Several
studies have demonstrated that, in IBVD, reduced
production of NO is due to an increase of CAV-1 expression
that retains the eNOS in a less-active state (Jia and Sowers,
2015). Indeed, CAV-1 overexpression has been found in
hyperlipidaemia (Yue et al., 2012; Kamada et al., 2016),
diabetes (Bucci et al., 2004; Vellecco et al., 2016a; Carantoni
et al., 1997; Clarkson et al., 1996; Ding and Triggle, 2005),
atherosclerosis (Fernández-Hernando et al., 2009; Pavlides
et al., 2014) and pulmonary hypertension (Gilbert et al.,
2016; Mu et al., 2016).
Theoretically, biosynthesis of H2S should also be impaired
in IBVD, as this gasotransmitter is, like NO, mainly produced
in endothelium. In line with this hypothesis, there is a
progressive reduction of H2S levels in plasma and vascular
tissues of non-obese diabetic mice (Brancaleone et al., 2008).
Also, in the spontaneous hypertensive rat (SHR), expression
of CSE in blood vessels is decreased, accompanied by a
reduction of plasma levels of H2S (Ahmad et al., 2012; Bucci
et al., 2014). Again, in a rat model of chronic kidney disease,
CBS, CSE and 3-MST in the kidney are down-regulated
(Aminzadeh and Vaziri, 2012) and H2S content falls. Such
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changes have also been shown in the activation of the renin-
angiotensin system associated with diabetic nephropathy
(Xue et al., 2013).
The protective role of H2S in the cardiovascular system,
and consequently its impairment in IBVD, has been
suggested by several studies. Thus, administration of H2S-
donors ameliorates ischaemia-induced heart failure in mice
and genetic overexpression of CSE improves left ventricular
performance and survival (Calvert et al., 2010). In SHR rats,
H2S-donors reduce systemic blood pressure (Bucci et al.,
2014) and myocardial ﬁbrosis (Meng et al., 2015) suggesting
a role for H2S deﬁciency in the development of these
pathologies. Decreased endogenous production of H2S has
also been linked to atherosclerosis, as CSE/ mice fed with
an atherogenic diet for 12 weeks, developed early lesions in
aorta, elevated plasma levels of LDL, hyperhomocysteinemia,
increased adhesion molecule expression, and enhanced
intimal proliferation. Replacement of H2S with a donor
inhibited such accelerated atherosclerosis development
(Mani et al., 2013). In patients with acute coronary syndrome,
the low concentration of circulating H2S was associated with
increased levels of CCL2 and CX3CL1, two monocyte
chemokines involved in the pathogenesis of atherosclerosis
(Gao et al., 2015).
H2S has been recognized also as an endogenousmodulator
of leukocyte–mediated inﬂammation (Whiteman et al., 2004).
Using intravitalmicroscopy in amurine air pouchmodel,H2S-
donors inhibited aspirin-induced leukocyte adherence in
mesenteric venules and leukocyte inﬁltration (Zanardo et al.,
2006). By using a complementary approach, several studies
have shown that inhibition of CSE activity can mimic or
worsen some pathological aspects of IBVD. For instance,
Zanardo and colleagues show that inhibition of H2S synthesis
promotes leukocyte inﬁltration (Zanardo et al., 2006). In
cultured renalmesangial cells, CSE blockade by PAG increased
generation of ROS, similar to that observed in a high glucose
environment (Xue et al., 2013). Also in apoE/mice fed with
a Western diet, PAG treatment enhanced the atherosclerotic
lesion area, the content of lipids and macrophages, and was
associated with lower plasma NO levels and protein
S-nitrosylation, implying that H2S could modulate athero-
sclerosis progression (Lin et al., 2016). However, while the
involvement of NO in IBVD has been relatively well deﬁned,
that of H2S is not as clear, in terms of the molecular
mechanisms involved. This lack of information is most likely
due to the lack of selective inhibitors of the different H2S
generating enzymes, along with less knowledge of the
mechanisms of activation of H2S generating enzymes,
compared with eNOS. This is an key issue, as all the enzymes
are constitutively expressed.
The gas paradigm in IBVD: A central role for
cGMP/PKG pathway?
Coming back to the ‘gas paradigm’, taking in account all the
data so far available, the endothelium is the key component
in their action in the vasculature. This is particularly true
under normal, healthy conditions, where the endothelium
synthesizes both gasotransmitters. In IBVD, the endothelial
impairment reduces both NO and H2S production. However,
this reduced level of endothelium-derived gasotransmitters
exposes a different aspect of the cooperation between NO
and H2S, because, while eNOS is only present in the
endothelium, CSE is expressed also in smooth muscle cells
(where it was ﬁrst described by Zhao et al., 2001). Thus, the
H2S biosynthesis in smooth muscle cells is still functional,
even when the endothelial synthesis is impaired. In this
way, H2S could provide a backup system for the vasculature
that becomes important (or is unmasked) when NO is
reduced, that is, in pathological conditions. In other words,
it could well be that the limited amount of NO provided by
a malfunctioning endothelium, together with the smooth
muscle cell-generated H2S, can still activate the signal
transduction pathway. In turn, H2S, by inhibiting PDE, allows
the cGMP to accumulate to the threshold necessary to trigger
the downstream signalling. Thus, a new question arises:
could H2S per se activate downstream signalling leading to
vasodilatation, even in a complete absence of NO? In other
words, could smooth muscle-derived H2S per se compensate
(even though partly) for the impairment of endothelial-
derived gasotransmitters? This is possible as incubation of
mouse aorta rings with sildenaﬁl prior to challenge of the
tissue with either an NO or H2S-donor cause opposing effects.
While sildenaﬁl potentiates NO-induced vasorelaxation by
contributing to cGMP rise by blocking PDE5, this does not
apply to H2S. Indeed, sildenaﬁl and H2S share the same
molecular target, therefore sildenaﬁl prevents and/or
competes with H2S for PDE binding, thereby reducing H2S-
induced vasorelaxation (Bucci et al., 2012). This functional
study has been further explored at molecular levels by
studying the role of PKG. Once synthesized, cGMP binds to
PKG, a kinase that activates the downstream signalling that
causes vasodilatation (Martinez-Ruiz et al., 2011). NaHS
enhanced phosphorylation of the vasodilator-stimulated
phosphoprotein (VASP) in aorta tissue in a time-dependent
manner, further suggesting that cGMP-dependent PKG is
activated, following exposure to H2S. This was conﬁrmed by
the ﬁnding that H2S–induced vasorelaxation was strongly
impaired in PKG/ mice and by using a selective PKG
inhibitor DT2 in wild type mice. Inhibition of PKG by DT2
also reduces the hypotension triggered by H2S administration
in vivo conﬁrming the role of PKG in H2S-induced
vasorelaxation (Bucci et al., 2012). The concept of
cooperation between NO and H2S signalling and a central
role for PKG has been also elegantly demonstrated by Coletta
and colleagues (Coletta et al., 2012). In their study, they not
only conﬁrm that H2S activated PKG and its downstream
effector VASP (Coletta et al., 2012) but also demonstrate, by
alternatively blocking CSE and eNOS, that the
cooperative action of the two gasotransmitters on increasing
and maintaining intracellular cGMP, is essential for
angiogenesis, wound healing and vasorelaxation (Coletta
et al., 2012).
Another important point to take in account is that the
action of H2S as an opener of KATP channels in blood vessels
is an action exclusive to H2S, and is not shared by NO.
Therefore, H2S-induced vasodilatation, due to KATP channels
activation in smooth muscle cells is still functional when
endothelial-derived action is impaired. However, the
contribution of this vasorelaxant mechanism could be
limited, as recent studies have shown that overproduction
of ROS in oxidative stress also disrupts vascular KATP channel
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activity (Miura et al., 2003; Ross and Armstead, 2003; Erdos
et al., 2004; Yang et al., 2010).
Taking all these results into consideration it is clear
that the balance between these two pathways is critically
altered in IBVD. The molecular basis of this interaction
is located within the sGC/cGMP/PKG pathway. Even
though NO and H2S share the same second messenger i.
e. cGMP, they act at different levels, with NO increasing
production of cGMP through stimulation of sGC and
H2S inhibiting cGMP degradation. This evidence taken
together with the ﬁnding that H2S can be produced also
in the smooth muscle deﬁnes the molecular basis of this
crosstalk in IBVD. Thus, in IBVD, there is a reduced
endothelial function with a decreased production of both
NO and H2S. However, the smooth muscle-derived H2S
can sustain vascular function by preserving the cGMP
levels up to the threshold necessary to trigger the cascade
of signalling, initiated by activation of PKG (Figure 1).
Nevertheless, this alternative source of H2S will itself fail
when the oxidative stress rises further, as the disease
increases in severity.
Conclusion and future perspectives
Considering the published results in the ﬁeld, it is clear that a
‘gas paradigm in the vascular system’ does exist, and that it
has an important role in controlling vascular tone in health
and in IBVD. Differences in the relative and interconnected
contributions of these two pathways can be assessed by
analysing the data available and dividing the results into
those obtained in physiological, and those obtained in
pathological, conditions. Through this exercise, it is also clear
that NO is undoubtedly the primary agent. Its beneﬁcial
action protects the vasculature and contributes to the
maintenance of the dynamic equilibrium between contra-
ction and dilatation of vessels, thus stabilising blood
pressure. However, even when the endothelium is
dysfunctional, the body still reacts in order to control the
vascular tone. In other words, the endothelium/smooth
muscle network must compensate for the reduction in NO
signalling. The identiﬁcation of H2S as an endogenous
vasodilator immediately suggested a possible cooperation
between these two gases in controlling vascular homeostasis.
Figure 1
Representative simpliﬁed scheme summarizing the main ﬁndings discussed. The diagram outlines the interaction between NO and H2S in
physiological (HEALTHY) and pathological (IBVD) conditions.HEALTHY: In endothelium, eNOS is bound to CAV-1, a resident protein of caveolae
that keeps eNOS in a less active state. When intracellular Ca2+ rises, Ca2+-calmodulin complex is formed and binds eNOS. This event contributes to
the displacement of eNOS from the negative control of CAV-1, leading to enzyme activation and NO production. At the same time, Ca2+-
calmodulin complex also activates CSE, leading to H2S biosynthesis. Being gases, NO and H2S diffuse into smooth muscle cells reaching their
own targets: sGC for NO and PDE for H2S. NO activates sGC leading to cGMP increase, while H2S inhibits PDE reducing cGMP degradation. cGMP,
by interacting with PKG, activates the downstream signalling that leads to vasodilatation. In addition, H2S acts as an opener of KATP channels,
expressed on smooth muscle cells leading to efﬂux of K+ ions from the cells. This event reduces calcium inﬂux into the cells contributing to vessel
relaxation. CSE is also expressed in smooth muscle cells where it actively produces H2S. IBVD: vascular diseases are characterized by an
overproduction of ROS that induce oxidative stress. This condition damages the endothelium, impairing both eNOS and CSE activity with
consequent reduction of both NO and H2S biosynthesis. The oxidative stress can also affect KATP channel activity. The limited amount of NO
provided by a damaged endothelium, still can activate the signal transduction pathway relying on the contribution of smooth muscle cell-
generated H2S that in turn, by inhibiting PDE, allows a production of cGMP within the threshold necessary to trigger the downstream signal. Solid
line: activation; dotted line: inhibition.
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At present, it appears that the H2S pathway becomes more
relevant when the NO pathway is impaired. However, more
and extensive investigations are needed to properly
understand the exact role of H2S in this context and, more
importantly, its relationship with NO.
There are still several key issues to be clariﬁed. While
eNOS/ mice show an obvious hypertensive phenotype,
conﬁrming the relevance of NO as a vasodilating mediator,
such a role is not clearly deﬁned for H2S. Indeed, CSE
/
mice display a less pronounced hypertension and, more
importantly, the increase of blood pressure is age-related
(Yang et al., 2008). Thus, the rise in blood pressure was
similar in homozygous and heterozygous mice until the
mice were 10 weeks of age, and only after this point, did
the blood pressure of CSE/ mice rise to about 10 mm
Hg higher than that of CSE/+ mice (Yang et al., 2008).
Moreover, another group have generated CSE/ mice and
found that both male and female CSE/ mice are
normotensive, but that they display an acute lethal
myopathy when fed with a low cysteine diet and show a
greater sensitivity to oxidative injury (Ishii et al., 2010).
However, it is also important to note that, in the
vasculature, H2S is formed by at least three different
enzymes - CSE, 3-MST, CBS - that are present in almost all
tissues with different ratios. Therefore, the lack of one of
them or its genetic deletion, even if that particular enzyme
is the main source of H2S in the examined cells and/or
tissue, does not completely deprive the tissue of this
gasotransmitter. Indeed, while an impairment of eNOS
function or gene deletion leads to a drastic reduction or
total loss of eNOS-derived NO, H2S production within
the CSE-/- endothelium can still be generated by 3MST
and/or CBS.
Even though the use in therapy of NO-donors appeared
to be the ﬁrst logical choice, it did not lead to new drugs.
Indeed, if we evaluate how much of our knowledge of NO
has been translated into therapeutic approaches, it is
obvious that very little of the relatively large amount of
information about NO has been translated into
therapeutically useful agents or procedures. At present,
there is still only nitroglycerine, the main drug used for
more than two centuries, in acute angina pectoris pain.
However, the therapeutic use of this drug is strongly limited
by the marked, uncontrolled hypotensive effects and by
tolerance. Indeed, these limitations apply to all the new
NO-donors developed and they remain as pharmacological,
preclinical tools. In this scenario, could the H2S-donors be
developed as a more practical therapeutic approach in
IBVD? Being less potent vasodilators than NO, H2S-donors
could be used without affecting systemic blood pressure.
Indeed, no changes in blood pressure were observed in
human volunteers, receiving intravenous Na2S, up to a dose
of 0.2 mg·kg1 (Toombs et al., 2010).
In this context, in the current literature there are some
clinical and preclinical data suggesting that sulphydrylated
ACE inhibitors exert additional beneﬁcial effects on the
vasculature, apart from ACE inhibition, effects that cannot
be explained solely through changes in the NO pathway.
For instance, H2S derived from S-zofenopril accounts for
the additional beneﬁcial effects on vasculature and systemic
blood pressure (Bucci et al., 2014). S-Zofenopril is a pro-drug
and, among the four possible diastereoisomers, it is the only
isomer active on ACE and used in therapy. The active
metabolite of S-zofenopril, namely S-zofenoprilat, has a
free thiol and, acting as an H2S-donor, improves vascular
reactivity, beyond ACE inhibition (Bucci et al., 2014). This
hypothesis has been conﬁrmed by the ﬁnding that the
inactive diastereoisomer R-zofenoprilat, even though it does
notmodify blood pressure in SHR, retains the beneﬁcial effect
on SHR vascular function and restores plasma and tissue H2S
levels (Bucci et al., 2014). Such protective actions can be
ascribed to stimulation of H2S signalling, rather than to a
generic antioxidant property, as it is well-known that
antioxidants are not efﬁcacious in this clinical setting (Pasini
et al., 2007). Similarly, Monti and co-authors have found that
S-zofenoprilat, in a CSE/H2S-mediated manner, abolished all
the inﬂammatory features induced by IL-1β in human
umbilical vein endothelial cells, especially the NF-κB/COX-
2/prostanoid pathway (Monti et al., 2016). Again,
pretreatment with S-zofenopril signiﬁcantly augmented both
plasma and myocardial H2S and NO levels in mice and
plasma H2S in pigs, as well as reducing myocardial infarct size
and cardiac troponin I levels after I/R injury (Donnarumma
et al., 2016). These ﬁndings taken together, suggest that it is
indeed feasible to develop H2S-releasing drugs, as therapeutic
agents in IBVD.
Another possible approach to increase H2S content in
blood vessels is to stimulate the endogenous molecular
machinery and to enhance H2S biosynthesis (Hine et al.,
2015). It is known that dietary restriction (DR) without
malnutrition, comprises many alimentary regimens that
exert several beneﬁts such as longevity and stress resistance
(Fontana et al., 2010., Miller et al., 2005). In this context, Hine
and colleagues have shown that, in a mouse model of DR,
restriction of sulfur-containing amino acids increased CSE
expression, resulting in increased H2S production and
protection from hepatic ischaemia-reperfusion injury.
Pharmacological and genetic inhibition of CSE reduced H2S
production and blocked the DR-mediated stress resistance,
conﬁrming the role of CSE-derived H2S in this phenomenon
(Hine et al., 2015).
In conclusion, these two gases, NO and H2S, cooperate in
maintaining vascular homeostasis. Under physiological
conditions, the key player in the gas paradigm is NO.
However, under pathological conditions, as in IBVD, the
balance between these two pathways changes and the role
of H2S becomes more relevant as a backup, rescue system,
taking advantage from the fact that its biosynthesis is not
restricted to the endothelium. Unravelling the molecular
mechanisms underlying the interaction of these two
gasotransmitters in disease may lead to the development of
new therapeutic approaches.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Southan
et al., 2016), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2015/16 (Alexander et al.,
2015).
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